Temporal Trends and Outcomes in Liver Transplantation for Recipients With HIV Infection in Europe and United States

被引:24
作者
Campos-Varela, Isabel [1 ,2 ]
Dodge, Jennifer L. [3 ]
Berenguer, Marina [4 ]
Adam, Rene [5 ]
Samuel, Didier [5 ,6 ]
Di Benedetto, Fabrizio [7 ]
Karam, Vincent [5 ]
Belli, Luca S. [8 ]
Duvoux, Christophe [9 ]
Terrault, Norah A. [10 ]
机构
[1] Hosp Univ Vall dHebron, Vall dHebron Inst Recerca, Dept Internal Med, Liver Unit, Barcelona 08095, Spain
[2] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
[3] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA
[4] Univ Med, La Fe Univ Hosp, IISLaFe, Liver Unit,Ciberehd, Valencia, Spain
[5] Univ Paris Sud Villejuif, Hop Paul Brousse, AP HP, Ctr Hepatobiliaire, Paris, France
[6] Univ Paris Sud Paris Saclay, Paris, France
[7] Univ Modena & Reggio Emilia, Hepatopancreatobiliary Surg & Liver Transplantat, Modena, Italy
[8] Osped Niguarda Ca Granda, Dept Hepatol & Gastroenterol, Milan, Italy
[9] Paris Est Univ UPEC, Univ Hosp Henri Mondor, AP HP, Dept Hepatol, Creteil, France
[10] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C; HEPATOCELLULAR-CARCINOMA; DEATH; INDIVIDUALS; PREVALENCE; SOFOSBUVIR; RECURRENCE; MORTALITY; THERAPY;
D O I
10.1097/TP.0000000000003107
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We evaluated trends and outcomes of liver transplantation (LT) recipients with/without HIV infection. Methods. LT recipients between 2008 and 2015 from the United Network for Organ Sharing and Organ Procurement and Transplantation Network and European Liver Transplant Registry were included. Trends and characteristics related to survival among LT recipients with HIV infection were determined. Results. Among 73 206 LT patients, 658 (0.9%) were HIV-infected. The proportion of LT HIV-infected did not change over time (P-trend = 0.16). Hepatitis C virus (HCV) as indication for LT decreased significantly for HIV-infected and HIV-uninfected patients (P-trends = 0.008 and <0.001). Three-year cumulative graft survival in LT recipients with and without HIV infection was 64.4% and 77.3%, respectively (P< 0.001), with improvements over time for both, but with HIV-infected patients having greater improvements (P-trends = 0.02 and 0.03). Adjusted risk of graft loss was 41% higher in HIV-infected versus HIV-uninfected (adjusted hazard ratio [aHR], 1.41;P< 0.001). Among HIV-infected, model of end-stage liver disease (aHR, 1.04;P< 0.001), body mass index <21 kg/m(2)(aHR, 1.61;P= 0.006), and HCV (aHR, 1.83;P< 0.001) were associated with graft loss, whereas more recent period of LT 2012-2015 (aHR, 0.58;P= 0.001) and donor with anoxic cause of death (aHR, 0.51;P= 0.007) were associated with lower risk of graft loss. Conclusions. Patients with HIV infection account for only 1% of LTs in United States and Europe, with fewer LT for HCV disease over time. A static rate of LT among HIV-infected patients may reflect improvements in cirrhosis management and/or persistent barriers to LT. Graft and patient survival among HIV-infected LT recipients have shown improvement over time.
引用
收藏
页码:2078 / 2086
页数:9
相关论文
共 23 条
[1]   Pharmacokinetic Study of Raltegravir in HIV-Infected Patients With End-Stage Liver Disease: The LIVERAL-ANRS 148 Study [J].
Barau, Caroline ;
Braun, Josephine ;
Vincent, Corine ;
Haim-Boukobza, Stephanie ;
Molina, Jean-Michel ;
Miailhes, Patrick ;
Fournier, Isabelle ;
Aboulker, Jean-Pierre ;
Vittecoq, Daniel ;
Duclos-Vallee, Jean-Charles ;
Taburet, Anne-Marie ;
Teicher, Elina .
CLINICAL INFECTIOUS DISEASES, 2014, 59 (08) :1177-1184
[2]   Liver-related Events in Human Immunodeficiency Virus-infected Persons With Occult Cirrhosis [J].
Benmassaoud, Amine ;
Nitulescu, Roy ;
Pembroke, Thomas ;
Halme, Alex S. ;
Ghali, Peter ;
Deschenes, Marc ;
Wong, Philip ;
Klein, Marina B. ;
Sebastiani, Giada .
CLINICAL INFECTIOUS DISEASES, 2019, 69 (08) :1422-1430
[3]   Global trends and predictions in hepatocellular carcinoma mortality [J].
Bertuccio, Paola ;
Turati, Federica ;
Carioli, Greta ;
Rodriguez, Teresa ;
La Vecchia, Carlo ;
Malvezzi, Matteo ;
Negri, Eva .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :302-309
[4]   Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy [J].
Campos-Varela, I. ;
Moreno, A. ;
Morbey, A. ;
Guaraldi, G. ;
Hasson, H. ;
Bhamidimarri, K. R. ;
Castells, L. ;
Grewal, P. ;
Banos, I. ;
Bellot, P. ;
Brainard, D. M. ;
McHutchison, J. G. ;
Terrault, N. A. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (12) :1319-1329
[5]   Sofosbuvir, Simeprevir, and Ribavirin for the Treatment of Hepatitis C Virus Recurrence in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Liver Transplant Recipients [J].
Campos-Varela, Isabel ;
Straley, Stephanie ;
Agudelo, Eliana Z. ;
Carlson, Laurie ;
Terrault, Norah A. .
LIVER TRANSPLANTATION, 2015, 21 (02) :272-274
[6]   Advances in Therapy for HIV/Hepatitis C Virus-Coinfected Patients in the Liver Transplant Setting [J].
Campos-Varela, Isabel ;
Peters, Marion G. ;
Terrault, Norah A. .
CLINICAL INFECTIOUS DISEASES, 2015, 60 (01) :108-116
[7]   Trends in Comorbid Conditions Among Medicaid Enrollees With HIV [J].
Cole, Megan B. ;
Galarraga, Omar ;
Rahman, Momotazur ;
Wilson, Ira B. .
OPEN FORUM INFECTIOUS DISEASES, 2019, 6 (04)
[8]   Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus [J].
Duclos-Vallee, Jean-Charles ;
Feray, Cyrille ;
Sebagh, Mylene ;
Teicher, Elina ;
Roque-Afonso, Anne-Marie ;
Roche, Bruno ;
Azoulay, Daniel ;
Adam, Rene ;
Bismuth, Henri ;
Castaing, Denis ;
Vittecoq, Daniel ;
Satnuel, Didier .
HEPATOLOGY, 2008, 47 (02) :407-417
[9]   Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis [J].
Farahani, Mansour ;
Mulinder, Holly ;
Farahani, Alexander ;
Marlink, Richard .
INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (07) :636-650
[10]   Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients [J].
Frassetto, Lynda ;
Floren, Leslie ;
Barin, Burc ;
Browne, Matthew ;
Wolfe, Alan ;
Roland, Michelle ;
Stock, Peter ;
Carlson, Laurie ;
Christians, Uwe ;
Benet, Leslie .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (08) :442-451